Tudor Investment Corp ET AL Invests $560,000 in Collegium Pharmaceutical, Inc. $COLL

Tudor Investment Corp ET AL purchased a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,010 shares of the specialty pharmaceutical company’s stock, valued at approximately $560,000. Tudor Investment Corp ET AL owned 0.05% of Collegium Pharmaceutical at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Federated Hermes Inc. grew its holdings in Collegium Pharmaceutical by 67.0% during the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 350 shares in the last quarter. Hantz Financial Services Inc. raised its stake in Collegium Pharmaceutical by 137.7% in the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 993 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after buying an additional 2,190 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 304.6% during the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after acquiring an additional 2,294 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Collegium Pharmaceutical by 444.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,551 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 2,899 shares during the last quarter.

Analyst Upgrades and Downgrades

COLL has been the topic of several research analyst reports. Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Barclays lowered their price objective on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research note on Friday, January 9th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Needham & Company LLC restated a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Finally, Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $53.40.

Collegium Pharmaceutical Stock Up 3.4%

NASDAQ:COLL opened at $33.07 on Wednesday. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.57 and a quick ratio of 1.48. The company’s fifty day moving average price is $41.35 and its 200-day moving average price is $41.66. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $50.79. The firm has a market capitalization of $1.05 billion, a P/E ratio of 19.34 and a beta of 0.67.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). The business had revenue of $205.45 million for the quarter, compared to analyst estimates of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.77 earnings per share. As a group, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 49,976 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the sale, the executive vice president owned 71,770 shares in the company, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total transaction of $488,041.92. Following the sale, the executive vice president directly owned 77,071 shares in the company, valued at $2,691,319.32. The trade was a 15.35% decrease in their position. The SEC filing for this sale provides additional information. 2.51% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.